ArticleAnnals of hematology2026

High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort.

Francesco Mendicino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.